Benzinga•2026-04-15
Microsoft To $500? Here Are 10 Top Analyst Forecasts For WednesdayORKA — Oruka Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
$69.00+129.24%Market cap2.17B
- Latest Close
- $69
- 30-Day Move
- +129.2%
- Market Cap
- $2.2B
- Shares Outstanding
- 49,540,000
- P/B Ratio
- 3.11
- ROE
- -22.3%
Analyst consensus: Buy · 20 analysts
NASDAQ:ORKABiotechnology / BiotechnologyDelayed public snapshot
Oruka Therapeutics Inc
A read-only Alphactor snapshot forOruka Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$69
30-Day Move
+129.2%
Market Cap
$2.2B
Shares Outstanding
49,540,000
P/B Ratio
3.11
ROE
-22.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$69.00
+129.2%last 90 delayed daily bars
Market cap$2.2B
90D High
$70.50
90D Low
$25.23
Avg Volume
731,880
What stands out
Net margin is -26.3%, useful for comparing ORKA against peers in Biotechnology.
ORKA is up 129.2% over the last 30 trading days shown on this page.
Latest operating income is $-34M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
69.4%
Fundamentals snapshot
Latest Close
$69
30-Day Move
+129.2%
Market Cap
$2.2B
Shares Outstanding
49,540,000
P/B Ratio
3.11
ROE
-22.3%
ROA
-21.6%
Operating Margin
-40.3%
Net Margin
-26.3%
Debt / Equity
0
Current Ratio
22.37
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-34M
Net Income
$-30M
Gross Margin
--
Net Margin
-2627.0%
Current Ratio
22.37
Debt / Equity
0.00
Quality snapshot
Altman Z
65.82
Safe
Piotroski
1
Weak (0-3)
Cash Conversion
0.84x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025-12-31 | $0 | $-122M | $-105M | $-88M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-15
Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$2M
Buys
0
Sells
24
Buy Value
$0
Sell Value
$2M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | Goncalves Joana | M | 3,500 | $0.00 |
| 2026-04-15 | Goncalves Joana | M | 3,500 | $0.00 |
| 2026-04-15 | Goncalves Joana | Sell | 500 | $67.38 |
| 2026-04-15 | Goncalves Joana | Sell | 2,273 | $66.56 |
| 2026-04-15 | Goncalves Joana | Sell | 4,227 | $65.73 |
| 2026-04-15 | Goncalves Joana | M | 3,500 | $7.80 |
| 2026-04-15 | Goncalves Joana | M | 3,500 | $6.84 |
| 2026-03-16 | Sandler Laura Lee | Sell | 600 | $41.30 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,368,827 | 0.03% | 2025-12-31 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1,006,510 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 938,024 | 0.02% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 796,349 | 0.02% | 2026-03-31 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 710,786 | 0.01% | 2026-02-28 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 600,000 | 0.01% | 2026-02-28 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 553,410 | 0.01% | 2026-01-31 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 475,783 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-08-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$220M
+0.1%
Vanguard Group
Filed 2026-01-29
$74M
+38.1%
Geode Capital Management
Filed 2026-02-09
$29M
+36.6%
Citadel Advisors
Filed 2026-02-17
$22M
--
Charles Schwab
Filed 2026-02-13
$10M
+33.4%
Northern Trust
Filed 2026-02-17
$9M
+27.9%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.4
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
20
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.